Otsu, Japan

Naoto Ohi

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 8.4

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Otsu, JP (2012)
  • Osaka, JP (2013)

Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Naoto Ohi: Innovator in Antitumor Research

Introduction

Naoto Ohi is a prominent inventor based in Otsu, Japan, known for his significant contributions to the field of antitumor research. With a total of four patents to his name, Ohi has made strides in developing innovative compositions that aim to combat cancer effectively.

Latest Patents

Ohi's latest patents include an antitumor composition that combines various antitumor agents to significantly shrink tumors through synergistic action while minimizing side effects. This composition features compound (B) or a salt thereof, used in conjunction with antitumor agent (A), which encompasses a range of agents such as alkylating agents, CD20 recognition molecules, and tyrosine kinase inhibitors. Another notable patent is for a heterocyclic compound represented by General Formula (1), which contributes to pharmaceutical advancements in cancer treatment.

Career Highlights

Naoto Ohi is currently associated with Otsuka Pharmaceutical Company, Limited, where he continues to push the boundaries of medical research. His work has garnered attention for its potential to improve treatment outcomes for cancer patients.

Collaborations

Ohi collaborates with esteemed colleagues, including Mitsuhiro Okuno and Takeshi Kodama, to further enhance the impact of his research in the pharmaceutical industry.

Conclusion

Naoto Ohi's innovative work in antitumor research exemplifies the vital role of inventors in advancing medical science. His contributions are paving the way for more effective cancer treatments, showcasing the importance of collaboration and innovation in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…